MIT engineers have developed a novel, gel-based drug delivery system designed to coat the esophageal lining and transport medication directly into the tissue. By utilizing a hydrogel combined with permeability-enhancing bile salts, this approach aims to treat disorders like eosinophilic esophagitis and Crohn’s disease while avoiding the systemic side effects of traditional immunosuppressant drugs, according to a study published in Nature Biomedical Engineering.
How does the new hydrogel formulation work?
The formulation functions by increasing the permeability of the esophageal wall, a notoriously difficult barrier for medication to cross. According to lead author Christina Karavasili of Aristotle University of Thessaloniki, the gel uses bile salts—specifically sodium chenodeoxycholate and sodium cholate—to temporarily loosen cell-cell junctions. This allows larger therapeutic molecules, such as the antibody infliximab, to pass into the mucosal tissue. The hydrogel’s viscous consistency ensures the medication remains on the esophageal surface long enough to facilitate this absorption, rather than passing through the digestive tract too quickly.
The human esophagus is lined with stratified squamous epithelium, a tissue layer so dense that it is naturally highly impermeable to most conventional drug molecules, making localized treatment a significant hurdle for gastroenterologists.
Why is site-directed delivery necessary for esophageal disorders?
Current treatment standards for esophageal inflammation often rely on systemic drugs that circulate throughout the entire body. Giovanni Traverso, an associate professor at MIT and gastroenterologist at Brigham and Women’s Hospital, notes that systemic immunosuppressants like infliximab can increase a patient’s risk of infection and other health complications. By delivering these agents directly to the site of inflammation, researchers hope to achieve therapeutic results while minimizing the exposure of the rest of the body to potent immunosuppressive agents.
How does this compare to existing treatment methods?
Clinicians currently face limited options for esophageal drug delivery. Traditional methods include:
- Systemic drugs: Effective at treating inflammation but associated with broad immunosuppressive side effects.
- Direct injections: Invasive and uncomfortable for the patient, requiring clinical visits for administration.
- Thickened steroid mixtures: Can remain in the esophagus longer than liquid drugs but struggle to penetrate the impermeable squamous cell layer.
The MIT-developed platform offers a middle ground: it provides the convenience of oral ingestion while achieving the targeted efficacy previously only possible through more invasive procedures.
What are the next steps for human clinical application?
Researchers are currently optimizing the hydrogel formulation for potential human trials. A primary focus is balancing the duration of adhesion; the gel must remain on the tissue long enough to deliver the drug without causing patient discomfort. According to the study, animal trials indicated that the loosening of cell-cell junctions is temporary, with tissue returning to its normal state within three days. Future studies will explore whether this platform can be adapted to deliver a wider variety of small-molecule drugs beyond the antibodies tested in the initial research.
When tracking advancements in drug delivery, look for platforms that utilize “permeability enhancers.” These compounds are changing how we treat tissues previously considered “off-limits” for oral medications.
Frequently Asked Questions
- What conditions could this gel treat?
- The researchers are targeting conditions like eosinophilic esophagitis and esophageal inflammation caused by Crohn’s disease.
- Is the effect on the esophagus permanent?
- No. According to the MIT study, the loosening of cell junctions is temporary, and the tissue returns to its normal state within three days.
- Can this deliver any type of drug?
- The platform was designed to deliver antibodies like infliximab, but researchers are currently investigating its potential for other small-molecule drugs.
Are you interested in the future of precision medicine? Subscribe to our newsletter to receive the latest updates on biomedical engineering breakthroughs and emerging clinical treatments.
